Prescription Drugs
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir, also known as Tamiflu.
The House Energy and Commerce Subcommittee on Health today hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain.”
The issue of affordability, including health care affordability, is front and center this year and will be part of this year's congressional and administration discussions, as well as the mid-term elections.
AHA Statement before the House Committee on Energy and Commerce
Health Subcommittee on “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain”
Absent any statutory consequences for not completing the OPPS Drug Acquisition Cost Survey (ODACS), it is wrong for CMS to tell hospitals and health systems that they “are to” complete it.
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver flexibilities for prescribing controlled substances via telemedicine.
The Department of Health and Human Services (HHS) and Drug Enforcement Administration (DEA) Dec. 30 released a temporary rule extending for the fourth time waiver flexibilities for prescribing controlled substances via telemedicine.
The Centers for Medicare & Medicaid Services (CMS) Nov. 28 released its proposed Policy and Technical Changes to the Medicare Advantage (MA) Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program and Programs of All-Inclusive Care for the Elderly for Contract Year (CY)…
In February, the American Hospital Association, The Pew Charitable Trusts and the American Society of Health-System Pharmacists convened organizations representing pharmacists, doctors, hospitals and health care systems, the U.S. Centers for Disease Control, State boards of pharmacy and the U.S.…
We applaud final Senate passage of the reauthorization of the Food and Drug Administration Safety and Innovation Act.